Clinical trial
Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO)
NCT01222286 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO)
- Lead sponsor
- Innate Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2010
- Completion date
- January 31, 2013
- Enrollment
- 30 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.